Hypen SR

Hypen SR1.5 mg

Tablet

Indapamide

Opsonin Pharma Ltd.

Product Code : 8352
MRP 84.00
10% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Hypen SR 1.5 mg

Hypen SR 1.5 mg is indicated in the treatment of essential hypertension . It is effective in treating hypertension in patients with renal function impairment, although its diuretic effect is reduced. Hypen SR 1.5 mg is also indicated for the treatment of salt and fluid retention associated with congestive heart failure.

Theropeutic Class

Thiazide diuretics & related drugs

Pharmacology

Hypen SR 1.5 mg is a diuretic antihypertensive. It appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. It has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance.

Dosage & Administration of Hypen SR 1.5 mg

One tablet daily preferably in the morning. In more sever case Hypen SR 1.5 mg can be combine with other categories of anti-hypertensive agent. The safety and effectiveness in pediatric patients have not been established

Dosage of Hypen SR 1.5 mg

One tablet daily preferably in the morning. In more sever case Hypen SR 1.5 mg can be combine with other categories of anti-hypertensive agent. The safety and effectiveness in pediatric patients have not been established

Interaction of Hypen SR 1.5 mg

Other antihypertensive: Hypen SR 1.5 mg may add to or potentiate the action of other antihypertensive drugs. Norepinephrine: Hypen SR 1.5 mg like thiazides, may decrease arterial responsiveness to norepinephrine. Lithium: In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity.

Contraindications

This drug must not be taken in the following conditions: Hypersensitivity to sulfonamides Severe renal failure Hepatic encephalopathy or severe hepatic failure Hypokalaemia

Side Effects of Hypen SR 1.5 mg

Side effects of Hypen SR 1.5 mg include headache, anorexia, gastric irritation,nausea, vomiting, constipation, diarrhoea etc.

Pregnancy & Lactation

There are no adequate and well-controlled studies in pregnant women and so Hypen SR 1.5 mg is not recommended. Mothers taking Hypen SR 1.5 mg should not breast feed.

Precautions & Warnings

Monitoring of potassium and uric acid serum levels is recommended, especially in subjects with a predisposition or sensitivity to hypokalemia and in patients with gout. Although no allergic manifestations have been reported during clinical trials, patients with a history of allergy to sulfonamide derivatives should be closely monitored.

Overdose Effects of Hypen SR 1.5 mg

Symptoms: These could include: allergies, skin rashes, epigastric pain, nausea, photosensitivity, dizziness, weakness and paraesthesia.Treatment: Treatment is supportive and symptomatic, directed at correcting the electrolyte abnormalities.

Storage Conditions

Store in a cool and dry place. Protect from light and moisture.

Drug Classes

Thiazide diuretics & related drugs

Mode Of Action

Hypen SR 1.5 mg is a diuretic antihypertensive. It appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. It has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance.

Pregnancy

There are no adequate and well-controlled studies in pregnant women and so Hypen SR 1.5 mg is not recommended. Mothers taking Hypen SR 1.5 mg should not breast feed.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.